Innate immunity as a driving force in renal disease  by de Heer, E. & Peters, D.J.M.
Kidney International (2008) 73       7
commentar y
induced cell death is EGFR/src/ERK signaling 
dependent in mouse proximal tubule cells. Am J 
Physiol Renal Physiol 2004; 287: F543–F549.
6. Xia Z, Dickens M, Raingeaud J et al. Opposing 
effects of ERK and JNK-p38 MAP kinases on 
apoptosis. Science 1995; 270: 1326–1331.
7. di Mari JF, Davis R, Safirstein RL. MAPK activation 
determines renal epithelial cell survival during 
oxidative injury. Am J Physiol Renal Physiol 1999; 
277: F195–F203.
8. Arany I, Megyesi JK, Kaneto H et al. Activation 
of ERK or inhibition of JNK ameliorates H2O2 
cytotoxicity in mouse renal proximal tubule cells. 
Kidney Int 2004; 65: 1231–1239.
9. Arany I, Megyesi J, Nelkin BD, Safirstein RL. STAT3 
attenuates EGFR-mediated ERK activation and 
cell survival during oxidant stress in mouse 
proximal tubular cells. Kidney Int 2006; 70: 
669–674.
10. Migliaccio E, Mele S, Salcini AE et al. Opposite 
effects of the p52shc/p46shc and p66shc 
splicing isoforms on the EGF receptor-MAP 
kinase-fos signalling pathway. EMBO J 1997; 16: 
706–716.
see original article on page 63
Innate immunity as a driving 
force in renal disease
E de Heer1 and DJM Peters2
Mrug et al. propose that innate immunity is a hallmark of progressive 
polycystic kidney disease (PKD). We propose that innate immunity 
is a driving force in the progression of many renal diseases. 
Renal epithelial cells are capable of expressing a large variety of 
proinflammatory genes resulting in the production of cytokines, 
chemokines, cell-adhesion molecules, and complement components. 
We suggest that future therapeutic interventions should be directed 
toward control of innate immunity in renal disease.
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Innate immunity plays a prominent role 
in many renal diseases. In teleost ﬁsh such 
as the sea lamprey and the rainbow trout, 
the anterior kidney functions as a second-
ary lymphoid organ.1 In mammalian spe-
cies, functional evolution of the kidney 
has developed in a diﬀerent direction: 
sorting of cells, proteins, electrolytes, 
and fluids. Remnants of our common 
vertebrate evolutionary past, however, 
are still present in human kidneys, as a 
multitude of proinﬂammatory genes can 
be activated in renal parenchyma.
Renal cells are capable of expressing 
Toll-like receptors2 with subsequent 
activation of mitogen-activated pro-
tein kinases, nuclear factor-κB, and 
activator protein-1 (Figure 1). Pathogen 
recognition receptors such as the Toll-
like receptors expressed by renal epi-
thelial cells contribute not only to the 
exacerbation of infection-mediated 
renal disease, but also to the self-per-
petuation of lupus nephritis by recog-
nition of nucleosomal autoantigens. 
Renal cells are also reported to express 
receptors for complement components.3 
Upon activation by proinﬂammatory 
cytokines such as interleukin-1β or 
interleukin-2, renal cells have been 
reported to express receptors for C3a, 
C3b, and C1q, resulting in the attrac-
tion, adhesion, and activation of inﬂam-
matory cells. Furthermore, renal cells 
have been shown to express costimu-
lation molecules for T-cell activation.4 
These transmembrane proteins are 
required for eﬀective activation of the 
CD3–T-cell receptor complex on both 
cytotoxic and helper T cells. Expression 
of B7 isoforms (CD80/86), inducible T-
cell co-stimulator ligand,  and CD40 has 
been described on renal epithelial cells, 
on mesangial cells, and on glomeru-
lar endothelial cells, with a profound 
impact on the course of transplant 
rejection. The above-mentioned mul-
titude of outside-in signaling by these 
receptors on epithelial cells results in 
the production of a variety of inﬂam-
matory cytokines and chemokines,5 
which attract inﬂammatory cells and 
subsequently amplify the inﬂammatory 
response in the kidney. Last but not 
least, both inﬂammation-activated and 
CD40L-activated renal cells have been 
demonstrated to produce complement 
components such as C3 (ref. 6), which 
seem more important in the course of 
renal disease than systemic production 
by the liver, as shown by elegant kidney 
transplantation experiments in C3-deﬁ-
cient mice by Pratt et al.7
With these factors, renal cells actively 
participate in the inﬂammatory response 
rather than responding to it. The pro-
pensity of renal cells to participate in 
immune responses is one of the limita-
tions encountered in kidney transplanta-
tion, in which human leukocyte antigen 
matching and prevention of ischemic 
injury are crucial for graft outcome.
The study by Mrug et al.8 (this issue) 
shows that innate immunity is also 
involved in the progression of polycystic 
kidney disease (PKD). Genome-wide 
expression analysis was performed in 
cpk mice, carrying a genetic mutation 
in the gene encoding the cilia-associ-
ated protein cystin, a model for reces-
sive polycystic disease. In severely as 
compared with mildly aﬀected animals, 
preferential upregulation was found of 
genes expressed by type II activated 
macrophages. In addition, increased 
levels of complement component C3 
were found both in cyst-lining and in 
non-cystic epithelia. It seems unlikely 
that the involvement of innate immunity 
remains conﬁned to the recessive form 
of polycystic disease. Both recessive 
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and dominant PKD is accompanied by 
tubulointerstitial ﬁbrosis and extensive 
inﬁltration by inﬂammatory cells, lead-
ing to deterioration of renal function in 
autosomal dominant PKD (ADPKD), 
and activation of mitogen-activated 
protein kinases and activator protein-1 
have been demonstrated in cystic kid-
neys from patients with ADPKD and in 
a corresponding mouse model.9 Expres-
sion proﬁling for a limited set of genes in 
patients with ADPKD shows increased 
expression of immune response genes 
in addition to genes associated with 
epithelial–mesenchymal transition and 
genes involved in extracellular matrix 
turnover.10 The study of Mrug et al.8 
underlines the involvement of innate 
immunity in a ﬁnal common pathway 
of progressive renal disease, which is 
independent of the underlying etiology. 
It also provides an opportunity for more 
selective therapeutic interventions aimed 
at innate immunity control by targeting 
for signaling pathways that result from 
activation of innate immunity receptors 
on renal cells. Interference with innate 
immunity has the advantage of control-
ling both the inﬂammatory response by 
the immune system and the responding 
renal cells. However, interference with 
innate immunity has the risk of inacti-
vation of our ﬁrst line of defense against 
bacterial and viral infections.
Future perspectives in human renal 
disease will require carefully designed 
treatment protocols after rigorous 
preselection by in vitro systems and 
experimental models.
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Figure 1 | Innate immunity and renal cells. AP-1, activator protein-1; CAM, cellular adhesion 
molecule; CRs, complement receptors; CSMs, co-stimulation molecules; IL, interleukin; IL-R, 
interleukin receptor; MAPK, mitogen-activated protein kinase; NF-κB, nuclear factor-κB; TLR, 
Toll-like receptor.
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